Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT03429426

Progression of Bone Erosions in Rheumatoid Arthritis Assessed by HR-pQCT and Conventional X-ray

Today, regular X-ray examination is not sufficiently sensitive for detecting progression of bone destruction in rheumatoid arthritis, but a new type of high-resolution CT scanner, the High-Resolution peripheral Quantitative Computed Tomography (HR-pQCT) can detect very early and minor joint injuries.

The purpose of this study is to use HR-pQCT techniques to look at the damage and disease activity progression in the hand and wrist joints of patients with rheumatoid arthritis.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Rheumatology, Aarhus University Hospital

Aarhus, 8000, Denmark

About this study

The design of the trial is an observational study with three distinct groups. At the start of the trial period and at one-year of follow-up, the trial subject will have their hand X-rayed by conventional radiography, and their metacarpophalangeal (MCP) joint and wrist scanned by HR-pQCT-Imaging. The 28-joint Disease Activity Score(DAS28-CRP), Health Assessment Questionnaire (HAQ), Visual analogue scale(VAS)-score for pain, fatigue and quality of life are performed to investigate the correlation between radiographic changes and disease activity. Blood samples are collected to investigate serological markers of bone metabolism and inflammation and the radiographic changes. The following groups are investigated:

  • Rheumatoid Arthritis(RA): Patients with RA ≥5 years according to the ACR/EULAR 2010 classification criteria or the American Rheumatism Association 1987 revised criteria are recruited from the outpatient clinic at the Department of Rheumatology, Aarhus University Hospital. Treatment will be adjusted according to the patient's need and according to national guidelines. (n=450)
  • Pre-RA patients: Patients with pre-RA, (joint pain, but no swelling and Anti-CCP 3 times above the upper limit) are recruited from the outpatient clinic at the Department of Rheumatology, Aarhus University Hospital. (n=75)
  • Healthy subjects: Healthy age- and sex-matched Individuals are recruited, as a control group, by posting at libraries in Aarhus, Aarhus University, Aarhus University Hospital and postings on the websites www.forsøgsperson.dk and www.Sundhed.dk. (N=100)

Who can participate

Only the study team can determine whether someone qualifies for participation.

Rheumatoid arthritis patients Inclusion criteria

  • Patients (> 18 years) with rheumatoid arthritis ≥5 years according to the ACR/EULAR (2010) classification criteria or American Rheumatism Association 1987 revised criteria for the patients who were diagnosed before 2010.
  • Patients who are receiving treatment on an outpatient basis.
  • Ability and willingness to give written informed consent and to meet the requirements of the trial protocol.

Exclusion criteria

  • Patients who have previously suffered trauma in the form of fracture or luxation of the hand are excluded.
  • Evidence of active malignant disease.
  • Hypo- or hyperthyroidism.
  • Hypocalcaemia.
  • Impaired renal function (eGFR <35ml/min).
  • Pregnancy. Pre-rheumatoid arthritis patients Inclusion criteria
  • Age over 18 years.
  • Anti-CCP 3 times the upper limit of the reference interval.
  • Arthralgia.
  • Ability and willingness to give written informed consent and to meet the requirements of the trial protocol.

Exclusion criteria

  • Pregnancy.
  • Swelling of joints. Verified by clinical ultrasound.
  • Patients who have previously suffered trauma in the form of fracture or luxation of the hand are excluded.
  • Evidence of malignant disease.
  • Hypo- or hyperthyroidism.
  • Hypocalcaemia. Healthy subjects Inclusion criteria
  • Age over 18 years.
  • No joint complaints.
  • Ability and willingness to give written informed consent and to meet the requirements of the trial protocol.

Exclusion criteria

  • Patients who have previously suffered trauma in the form of fracture or luxation of the hand are excluded.
  • Evidence of malignant disease.
  • Hypo- or hyperthyroidism.
  • Hypocalcaemia.
  • Impaired renal function (eGFR <35ml/min).
  • Earlier or present rheumatological disease or bone metabolic disease.
  • Positive anti-CCP.
  • Pregnancy.

Treatment and study plan

Primary outcomes

  1. Erosion changes by HR-pQCT

    Time frame: One year

    Changes in bone erosions volume in mm3 by HR-pQCT-imaging from baseline to one-year follow-up, in the three groups.

  2. Volumetric bone mineral density(vBMD) changes by HR-pQCT

    Time frame: One year

    Changes in volumetric bone mineral density(vBMD) in mgHA/cm3 by HR-pQCT-imaging from baseline to one-year follow-up, in the three groups.

  3. Erosion changes by HR-pQCT

    Time frame: One year

    Changes in bone erosions width in mm by HR-pQCT-imaging from baseline to one-year follow-up, in the three groups.

  4. Erosion changes by HR-pQCT

    Time frame: One year

    Changes in bone erosions depth in mm by HR-pQCT-imaging from baseline to one-year follow-up, in the three groups.

Secondary outcomes

  1. Radiographic erosion score

    Time frame: One year

    Change in Sharp/van der Heijde (SvH) score from baseline to one-year follow-up, in the three groups.

  2. CTX

    Time frame: one year

    Changes from baseline to one-year follow-up in C-terminal telopeptide (CTX) in pg/mL, in the three groups.

  3. P1NP

    Time frame: one year

    Changes from baseline to one-year follow-up in Procollagen type 1 N-terminal propeptide (P1NP) in pg/mL, in the three groups.

  4. BAP

    Time frame: one year

    Changes from baseline to one-year follow-up in Bone-specific alkaline phosphatase (BAP) in pg/mL, in the three groups.

  5. TNF-α

    Time frame: one year

    Changes from baseline to one-year follow-up in the Tumor necrosis factor-alfa (TNF-α) in pg/mL, in the three groups.

  6. RANK-L

    Time frame: one year

    Changes from baseline to one-year follow-up in RANK-Ligand (RANK-L) in pg/mL, in the three groups.

  7. OPG

    Time frame: one year

    Changes from baseline to one-year follow-up in Osteoprotegerin (OPG) in pg/mL, in the three groups.

  8. BGLAP

    Time frame: one year

    Changes from baseline to one-year follow-up in Osteocalcin (BGLAP) in pg/mL, in the three groups.

  9. SCL

    Time frame: one year

    Changes from baseline to one-year follow-up in Sclerostin(SCL) in pg/mL, in the three groups.

  10. Dkk-1

    Time frame: one year

    Changes from baseline to one-year follow-up in Dickkopf-related protein 1 (Dkk-1) in pg/mL, in the three groups.

  11. IL-1

    Time frame: one year

    Changes from baseline to one-year follow-up in Interleukins 1 (IL-1) in pg/mL, in the three groups.

  12. IL-6

    Time frame: one year

    Changes from baseline to one-year follow-up in Interleukins 6 (IL-6) in pg/mL, in the three groups.

  13. IL-15

    Time frame: one year

    Changes from baseline to one-year follow-up in Interleukins 15 (IL-15) in pg/mL, in the three groups.

  14. IL-16

    Time frame: one year

    Changes from baseline to one-year follow-up in Interleukins 16 (IL-16) in pg/mL, in the three groups.

  15. IL-17

    Time frame: one year

    Changes from baseline to one-year follow-up in Interleukins 17 (IL-17) in pg/mL, in the three groups.

  16. IL-22

    Time frame: one year

    Changes from baseline to one-year follow-up in Interleukins 22 (IL-22) in pg/mL, in the three groups.

  17. IL-33

    Time frame: one year

    Changes from baseline to one-year follow-up in Interleukins 33 (IL-33) in pg/mL, in the three groups.

  18. CCL11

    Time frame: one year

    Changes from baseline to one-year follow-up in Chemokine ligand 11 (CCL11) in pg/mL, in the three groups.

  19. CXCL13

    Time frame: one year

    Changes from baseline to one-year follow-up in Chemokine (C-X-C) motif ligand (CXCL13) in pg/mL, in the three groups.

  20. TRACP 5b

    Time frame: one year

    Changes from baseline to one-year follow-up in Tartrate-resistant acid phosphatase 5b (TRACP 5b) in pg/mL, in the three groups.

  21. CRP

    Time frame: one year

    Changes from baseline to one-year follow-up in C-reactive protein (CRP) in mg/L, in the three groups.

  22. Disease Activity Score

    Time frame: one year

    Disease Activity Score (DAS28-CRP) [2.0-10.0]

  23. Health Assessment Questionnaire

    Time frame: one year

    Health Assessment Questionnaire (HAQ) [0-3 HAQ Total Score]

  24. VAS for pain

    Time frame: one year

    Visual Analog Scale(VAS) for pain [0-100mm]

  25. VAS for fatigue

    Time frame: one year

    Visual Analog Scale(VAS) for fatigue [0-100mm]

  26. VAS for quality of life

    Time frame: one year

    Visual Analog Scale(VAS) for quality of life [0-100mm]

Other outcomes

  1. areal bone mineral density (aBMD)

    Time frame: one year

    aBMD in the lumbar spine, and the left hip by DXA, in RA patients

Sponsors and collaborators

Lead sponsor

Aarhus University Hospital

Other

Collaborators

  • University of Aarhus

Registry information

Official study title

An Observational Study of Bone Erosion Determination and Progression in Rheumatoid Arthritis Assessed by HR-pQCT and Conventional X-ray

Acronym: RACTX

Important dates

Study start
2018
Primary completion
2022
Study completion
2026
First posted
Feb 12, 2018
Registry last updated
Jan 13, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.